HomeNewsDilip bidani

Dilip Bidani

Jump to

Dr Lal PathLabs sees margins declining 200-300 bps in 2-3 yrs

It has been a fairly good quarter on account of the seasonal fevers, said Dilip Bidani, CFO, Dr Lal PathLabs in an interview with CNBC-TV18.
May outperform industry's 17% FY17 growth rate forecast: Dr Lal

Dilip Bidani, CFO of Dr Lal PathLabs expects margins to dilute by 200-300 bps in coming two to three years, but says that growth will be better than the expected industry growth of 16-17 percent in FY17.
Healthcare sector a shot in the arm for co: Dr Lal PathLabs

The diagnostics and pathology sector is expected to grow at 16-17 percent, says Dilip Bidani, CFO of Dr Lal PathLabs. He adds the company has seen a tremendous performance in a short time.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Dilip Bidani

Dr Lal PathLabs sees margins declining 200-300 bps in 2-3 yrs

May outperform industry's 17% FY17 growth rate forecast: Dr Lal

Healthcare sector a shot in the arm for co: Dr Lal PathLabs